Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

British Journal of Pharmacology

Volumn 143, Issue 2, 2004, Pages 247-250

  Costa, Barbara ^a   Giagnoni, Gabriella ^a   Franke, Chiara ^b   Trovato, Anna Elisa ^a   Colleoni, Mariapia ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cannabidiol; Cannabinoid; Carrageenan; Hyperalgesia; TRPV1

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CAPSAZEPINE; CARRAGEENAN; RIMONABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THERMAL STIMULATION;

ADMINISTRATION, ORAL; ANIMALS; BORNANES; CANNABIDIOL; CAPSAICIN; CARRAGEENAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HYPERALGESIA; INFLAMMATION; ITALY; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, DRUG; TIME FACTORS;

EID: 4744372178     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705920     Document Type: Article

References (19)

1. AMAYA, F., OH-HASHI, K., NARUSE, Y., IIJIMA, N., UEDA, M., SHIMOSATO, G., TOMINAGA, M., TANAKA, Y. & TANAKA, M. (2003). Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res., 963, 190-196.
2. BISOGNO, T., HANUS, L., DE PETROCELLIS, L., TCHILIBON, S., PONDE, D.E., BRANDI, I., SCHIANO MORIELLO, A., DAVIS, J.V., MECHOULAM, R. & DI MARZO, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 134, 845-852.
3. CALIGNANO, A., LA RANA, G., GIUFFRIDA, A. & PIOMELLI, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
4. CARLTON, S.M. & COGGESHALL, R.E. (2001). Peripheral capsaicin receptors increase in the inflamed hindpaw: a possible mechanism for peripheral sensitisation. Neurosci. Lett., 310, 53-56.
5. 9-tetrahydrocannabinol-induced antinociception in rats. Eur. J. Pharmacol., 384, 153-156.
6. CATERINA, M.J., LEFFLER, A., MALMBERG, A.B., MARTIN, W.J., TRAFTON, J., PETERSEN-ZEITZ, K.R., KOLTZENBURG, M., BASBAUM, A.I. & JULIUS, D. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science, 288, 306-313.
7. COSTA, B., COLLEONI, M., CONTI, S., PAROLARO, D., FRANKE, C., TROVATO, A.E. & GIAGNONI, G. (2004). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch. Pharmacol., 369, 294-299.
8. DAVIS, J.B., GRAY, J., GUNTHORPE, M.J., HATCHER, J.P., DAVEY, P.T., OVEREND, P., HARRIES, M.H., LATCHAM, J., CLAPHAM, C., ATKINSON, K., HUGHES, S.A., RANCE, K., GRAU, E., HARPER, A.J., PUGH, P.L., ROGERS, D.C., BINGHAM, S., RANDALL, A. & SHEARDOWN, S.A. (2000). Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature, 405, 183-187.
9. DI MARZO, V., LASTRES-BECKER, I., BISOGNO, T., DE PETROCELLIS, L., MILONE, A., DAVIS, J.B. & FERNANDEZ-RUIZ, J.J. (2001). Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol., 420, 123-131.
10. HARGREAVES, K.M., DUBNER, R., BROWN, S., FLORES, C. & JORIS, J. (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain, 32, 77-88.
11. MALFAIT, A.M., GALLILY, R., SUMARIWALLA, P.F., MALIK, A.S., ANDREAKOS, E., MECHOULAM, R. & FELDMANN, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A., 97, 9561-9566.
12. MECHOULAM, R., PARKER, L.A. & GALLILY, R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol., 42, 11S-19S.
13. PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129-180.
14. RAKHSHAN, F., DAY, T.A., BLAKELY, R.D. & BARKER, E.L. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther., 124, 315-322.
15. RASHID, M.H., INOUE, M., BAKOSHI, S. & UEDA, H. (2003). Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J. Pharmacol. Exp. Ther., 306, 709-717.
16. RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J-M, CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J-C & Le FUR, G. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644-650.
17. WATANABE, K., KAYANO, Y., MATSUNAGA, T., YAMAMOTO, I. & YOSHIMURA, H. (1996). Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol. Pharm. Bull., 19, 1109-1111.
18. ZIMMERMANN, M. (1983). Ethical guidelines for investigation of experimental pain in conscious animals. Pain, 16, 109-110.
19. ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SORGARD, M., DI MARZO, V., JULIUS, D. & HOGESTATT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457.